Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| SHOULDER INNOVATIONS, INC.SI · Entity 5607 | Director | October 05, 2026 | October 06, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
SHOULDER INNOVATIONS, INC.
Report date October 05, 2026 · Filed October 06, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 7,438 |
Reported balance
After 2026-10-05 transaction · row 1
1 source rowRow 1 · 2026-10-05 · Grant · Acquired 669 · Balance 7,438 F1: Represents an award of restricted stock units ("RSUs") received in lieu of cash retainer fees, which were fully vested as of the grant date. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock and has no expiration date. The Reporting Person voluntarily elected to defer receipt of the Common Stock issuable upon settlement of the RSUs until the Reporting Person's departure from the Board of Directors. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents an award of restricted stock units ("RSUs") received in lieu of cash retainer fees, which were fully vested as of the grant date. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock and has no expiration date. The Reporting Person voluntarily elected to defer receipt of the Common Stock issuable upon settlement of the RSUs until the Reporting Person's departure from the Board of Directors.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Inari Medical, Inc.
Report date February 19, 2025 · Filed February 20, 2025
Section 16 reporting ended · disclosed 2025-02-20. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy Child 1 | 0 |
Reported balance
After 2025-02-19 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2025-02-19 · Other · Disposed 1,550 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated January 6, 2025, by and among Stryker Corporation ("Parent"), Eagle 1 Merger Sub, Inc. ("Merger Sub"), and Inari Medical, Inc. ("Issuer") on February 19, 2025 (the "Effective Time"), Merger Sub merged with and into Issuer, with Issuer surviving as a wholly owned subsidiary of Parent upon consummation of the transactions contemplated by the Merger Agreement. At the Effective Time, each outstanding share of common stock of the Issuer ("Common Stock") was cancelled and converted into the right to receive $80.00 in cash (the "Merger Consideration"), without interest. |
| Common StockSEC Table I · non-derivative | IndirectBy Child 2 | 0 |
Reported balance
After 2025-02-19 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2025-02-19 · Other · Disposed 1,550 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated January 6, 2025, by and among Stryker Corporation ("Parent"), Eagle 1 Merger Sub, Inc. ("Merger Sub"), and Inari Medical, Inc. ("Issuer") on February 19, 2025 (the "Effective Time"), Merger Sub merged with and into Issuer, with Issuer surviving as a wholly owned subsidiary of Parent upon consummation of the transactions contemplated by the Merger Agreement. At the Effective Time, each outstanding share of common stock of the Issuer ("Common Stock") was cancelled and converted into the right to receive $80.00 in cash (the "Merger Consideration"), without interest. |
| Common StockSEC Table I · non-derivative | IndirectBy Child 3 | 0 |
Reported balance
After 2025-02-19 transaction · row 3
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 3 · 2025-02-19 · Other · Disposed 1,550 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated January 6, 2025, by and among Stryker Corporation ("Parent"), Eagle 1 Merger Sub, Inc. ("Merger Sub"), and Inari Medical, Inc. ("Issuer") on February 19, 2025 (the "Effective Time"), Merger Sub merged with and into Issuer, with Issuer surviving as a wholly owned subsidiary of Parent upon consummation of the transactions contemplated by the Merger Agreement. At the Effective Time, each outstanding share of common stock of the Issuer ("Common Stock") was cancelled and converted into the right to receive $80.00 in cash (the "Merger Consideration"), without interest. |
| Common StockSEC Table I · non-derivative | IndirectBy Spouse | 0 |
Reported balance
After 2025-02-19 transaction · row 4
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 4 · 2025-02-19 · Other · Disposed 1,000 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated January 6, 2025, by and among Stryker Corporation ("Parent"), Eagle 1 Merger Sub, Inc. ("Merger Sub"), and Inari Medical, Inc. ("Issuer") on February 19, 2025 (the "Effective Time"), Merger Sub merged with and into Issuer, with Issuer surviving as a wholly owned subsidiary of Parent upon consummation of the transactions contemplated by the Merger Agreement. At the Effective Time, each outstanding share of common stock of the Issuer ("Common Stock") was cancelled and converted into the right to receive $80.00 in cash (the "Merger Consideration"), without interest. |
| Common StockSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2025-02-19 transaction · row 6
2 source rows · reconciled sequenceRow 5 · 2025-02-19 · Grant · Acquired 20,393 · Balance 717,637 F2: Pursuant to the Merger Agreement, at the Effective Time, these performance-based restricted stock units vested based on deemed achievement of maximum performance. Row 6 · 2025-02-19 · Other · Disposed 717,637 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated January 6, 2025, by and among Stryker Corporation ("Parent"), Eagle 1 Merger Sub, Inc. ("Merger Sub"), and Inari Medical, Inc. ("Issuer") on February 19, 2025 (the "Effective Time"), Merger Sub merged with and into Issuer, with Issuer surviving as a wholly owned subsidiary of Parent upon consummation of the transactions contemplated by the Merger Agreement. At the Effective Time, each outstanding share of common stock of the Issuer ("Common Stock") was cancelled and converted into the right to receive $80.00 in cash (the "Merger Consideration"), without interest. F3: Includes 149,010 shares of restricted stock units ("RSUs"). At the Effective Time, each outstanding award of RSUs was canceled and converted into the right to receive an amount in cash equal to the product of the aggregate number of shares underlying such RSU immediately prior to the Effective Time, multiplied by the Merger Consideration. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $56.00 | Direct | 0 |
Reported balance
After 2025-02-19 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2025-02-19 · Disposition to issuer · Disposed 36,085 · Balance 0 F4: At the Effective Time, each outstanding option, whether vested or unvested, was cancelled and converted into the right to receive an amount of cash equal to the product of (i) the aggregate number of shares of Common Stock underlying such option immediately prior to the Effective Time, multiplied by (ii) the amount, if any, by which the Merger Consideration exceeds the exercise price per share of such option, subject to any applicable withholding taxes and in accordance with the terms of the Merger Agreement. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $58.44 | Direct | 0 |
Reported balance
After 2025-02-19 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2025-02-19 · Disposition to issuer · Disposed 44,693 · Balance 0 F4: At the Effective Time, each outstanding option, whether vested or unvested, was cancelled and converted into the right to receive an amount of cash equal to the product of (i) the aggregate number of shares of Common Stock underlying such option immediately prior to the Effective Time, multiplied by (ii) the amount, if any, by which the Merger Consideration exceeds the exercise price per share of such option, subject to any applicable withholding taxes and in accordance with the terms of the Merger Agreement. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated January 6, 2025, by and among Stryker Corporation ("Parent"), Eagle 1 Merger Sub, Inc. ("Merger Sub"), and Inari Medical, Inc. ("Issuer") on February 19, 2025 (the "Effective Time"), Merger Sub merged with and into Issuer, with Issuer surviving as a wholly owned subsidiary of Parent upon consummation of the transactions contemplated by the Merger Agreement. At the Effective Time, each outstanding share of common stock of the Issuer ("Common Stock") was cancelled and converted into the right to receive $80.00 in cash (the "Merger Consideration"), without interest.
F2: Pursuant to the Merger Agreement, at the Effective Time, these performance-based restricted stock units vested based on deemed achievement of maximum performance.
F3: Includes 149,010 shares of restricted stock units ("RSUs"). At the Effective Time, each outstanding award of RSUs was canceled and converted into the right to receive an amount in cash equal to the product of the aggregate number of shares underlying such RSU immediately prior to the Effective Time, multiplied by the Merger Consideration.
F4: At the Effective Time, each outstanding option, whether vested or unvested, was cancelled and converted into the right to receive an amount of cash equal to the product of (i) the aggregate number of shares of Common Stock underlying such option immediately prior to the Effective Time, multiplied by (ii) the amount, if any, by which the Merger Consideration exceeds the exercise price per share of such option, subject to any applicable withholding taxes and in accordance with the terms of the Merger Agreement.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 05, 2021 Filed Jan 7, 2021 22:46 UTC | Inari Medical, Inc. NARI · Entity 83035 | SaleCommon Stock | 8,514 | $78.81 | $671,024.10 |
DisclosureSEC source: 0001562180-21-000256 · primarydocument.xml · nonDerivative · entry 2 Hykes Andrew · CIK 0001806431 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 245,141 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 16, 2020. F3 · price: This transaction was executed in multiple trades at prices ranging from $78.52 to $79.42. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| January 05, 2021 Filed Jan 7, 2021 22:46 UTC | Inari Medical, Inc. NARI · Entity 83035 | SaleCommon Stock | 6,486 | $77.86 | $505,003.85 |
DisclosureSEC source: 0001562180-21-000256 · primarydocument.xml · nonDerivative · entry 1 Hykes Andrew · CIK 0001806431 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 253,655 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 16, 2020. F2 · price: This transaction was executed in multiple trades at prices ranging from $77.52 to $78.49. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| December 18, 2020 Filed Dec 22, 2020 00:06 UTC | Inari Medical, Inc. NARI · Entity 83035 | SaleCommon Stock | 7,170 | $69.35 | $497,247.39 |
DisclosureSEC source: 0001562180-20-007397 · primarydocument.xml · nonDerivative · entry 4 Hykes Andrew · CIK 0001806431 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 260,141 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 16, 2020. F5 · price: This transaction was executed in multiple trades at prices ranging from $68.72 to $69.64. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| December 18, 2020 Filed Dec 22, 2020 00:06 UTC | Inari Medical, Inc. NARI · Entity 83035 | SaleCommon Stock | 3,859 | $70.47 | $271,925.98 |
DisclosureSEC source: 0001562180-20-007397 · primarydocument.xml · nonDerivative · entry 3 Hykes Andrew · CIK 0001806431 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 267,311 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 16, 2020. F4 · price: This transaction was executed in multiple trades at prices ranging from $69.90 to $70.89. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| December 18, 2020 Filed Dec 22, 2020 00:06 UTC | Inari Medical, Inc. NARI · Entity 83035 | SaleCommon Stock | 12,202 | $71.41 | $871,291.13 |
DisclosureSEC source: 0001562180-20-007397 · primarydocument.xml · nonDerivative · entry 2 Hykes Andrew · CIK 0001806431 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 271,170 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 16, 2020. F3 · price: This transaction was executed in multiple trades at prices ranging from $70.90 to $71.86. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| December 18, 2020 Filed Dec 22, 2020 00:06 UTC | Inari Medical, Inc. NARI · Entity 83035 | SaleCommon Stock | 4,169 | $72.13 | $300,707.05 |
DisclosureSEC source: 0001562180-20-007397 · primarydocument.xml · nonDerivative · entry 1 Hykes Andrew · CIK 0001806431 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 283,372 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 16, 2020. F2 · price: This transaction was executed in multiple trades at prices ranging from $71.92 to $72.49. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| November 30, 2020 Filed Dec 3, 2020 00:28 UTC | Inari Medical, Inc. NARI · Entity 83035 | SaleCommon Stock | 6,116 | $68.81 | $420,862.14 |
DisclosureSEC source: 0001562180-20-007026 · primarydocument.xml · nonDerivative · entry 4 Hykes Andrew · CIK 0001806431 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 287,541 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 16, 2020. F5 · price: This transaction was executed in multiple trades at prices ranging from $68.54 to $69.06. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| November 30, 2020 Filed Dec 3, 2020 00:28 UTC | Inari Medical, Inc. NARI · Entity 83035 | SaleCommon Stock | 10,772 | $67.87 | $731,080.56 |
DisclosureSEC source: 0001562180-20-007026 · primarydocument.xml · nonDerivative · entry 3 Hykes Andrew · CIK 0001806431 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 293,657 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 16, 2020. F4 · price: This transaction was executed in multiple trades at prices ranging from $67.53 to $68.51. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| November 30, 2020 Filed Dec 3, 2020 00:28 UTC | Inari Medical, Inc. NARI · Entity 83035 | SaleCommon Stock | 9,112 | $67.11 | $611,481.72 |
DisclosureSEC source: 0001562180-20-007026 · primarydocument.xml · nonDerivative · entry 2 Hykes Andrew · CIK 0001806431 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 304,429 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 16, 2020. F3 · price: This transaction was executed in multiple trades at prices ranging from $66.53 to $67.52. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| November 30, 2020 Filed Dec 3, 2020 00:28 UTC | Inari Medical, Inc. NARI · Entity 83035 | SaleCommon Stock | 1,400 | $65.69 | $91,971.46 |
DisclosureSEC source: 0001562180-20-007026 · primarydocument.xml · nonDerivative · entry 1 Hykes Andrew · CIK 0001806431 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 313,541 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 16, 2020. F2 · price: This transaction was executed in multiple trades at prices ranging from $65.43 to $66.25. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| May 27, 2020 Filed May 27, 2020 22:29 UTC | Inari Medical, Inc. NARI · Entity 83035 | ConversionSeries C Preferred Stock · Derivative | 13,570 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-032405 · doc4.xml · derivative · entry 6 Hykes Andrew · CIK 0001806431 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 13,570 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Upon the closing of the Issuer's initial public offering, each share of preferred stock automatically converted into shares of the Issuer's common stock on a one-for-one basis. F1 · price: Upon the closing of the Issuer's initial public offering, each share of preferred stock automatically converted into shares of the Issuer's common stock on a one-for-one basis. F1 · derivative.exercise_date: Upon the closing of the Issuer's initial public offering, each share of preferred stock automatically converted into shares of the Issuer's common stock on a one-for-one basis. F1 · derivative.expiration_date: Upon the closing of the Issuer's initial public offering, each share of preferred stock automatically converted into shares of the Issuer's common stock on a one-for-one basis. Read SEC document |
| May 27, 2020 Filed May 27, 2020 22:29 UTC | Inari Medical, Inc. NARI · Entity 83035 | PurchaseCommon Stock | 1,550 | $19.00 | $29,450.00 |
DisclosureSEC source: 0001209191-20-032405 · doc4.xml · nonDerivative · entry 5 Hykes Andrew · CIK 0001806431 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Child 3 Disclosed balance after: 1,550 Read SEC document |
| May 27, 2020 Filed May 27, 2020 22:29 UTC | Inari Medical, Inc. NARI · Entity 83035 | PurchaseCommon Stock | 1,550 | $19.00 | $29,450.00 |
DisclosureSEC source: 0001209191-20-032405 · doc4.xml · nonDerivative · entry 4 Hykes Andrew · CIK 0001806431 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Child 2 Disclosed balance after: 1,550 Read SEC document |
| May 27, 2020 Filed May 27, 2020 22:29 UTC | Inari Medical, Inc. NARI · Entity 83035 | PurchaseCommon Stock | 1,550 | $19.00 | $29,450.00 |
DisclosureSEC source: 0001209191-20-032405 · doc4.xml · nonDerivative · entry 3 Hykes Andrew · CIK 0001806431 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Child 1 Disclosed balance after: 1,550 Read SEC document |
| May 27, 2020 Filed May 27, 2020 22:29 UTC | Inari Medical, Inc. NARI · Entity 83035 | PurchaseCommon Stock | 1,000 | $19.00 | $19,000.00 |
DisclosureSEC source: 0001209191-20-032405 · doc4.xml · nonDerivative · entry 2 Hykes Andrew · CIK 0001806431 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 1,000 Read SEC document |
| May 27, 2020 Filed May 27, 2020 22:29 UTC | Inari Medical, Inc. NARI · Entity 83035 | ConversionCommon Stock | 13,570 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-032405 · doc4.xml · nonDerivative · entry 1 Hykes Andrew · CIK 0001806431 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 314,941 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Upon the closing of the Issuer's initial public offering, each share of preferred stock automatically converted into shares of the Issuer's common stock on a one-for-one basis. F1 · price: Upon the closing of the Issuer's initial public offering, each share of preferred stock automatically converted into shares of the Issuer's common stock on a one-for-one basis. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.